

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
CAMDEN DIVISION**

IN RE: VALSARTAN,
LOSARTAN, AND IRBESARTAN
PRODUCTS LIABILITY
LITIGATION

No. 1:19-md-2875-RBK
Hon. Robert B. Kugler
Hon. Karen M. Williams

(Document Filed Electronically)

RULE 7.1.1(a) DISCLOSURE STATEMENT

Defendants *Aurobindo Pharma USA, Inc., Aurobindo Pharma LTD., and Aurolife Pharma, LLC*. (collectively the “Aurobindo entities”) hereby notify the Court, pursuant to Local Rule 7.1.1(a), that there is no person or entity not a party to this action providing funding for any portion of the Aurobindo entities’ attorney’s fees or expenses of litigation in exchange for a contingent financial interest based upon the results of the litigation or a non- monetary result that is not in the nature of a personal or bank loan or insurance.

Dated: July 22, 2021

Respectfully submitted,

CIPRIANI & WERNER, P.C.

/s/ Jessica M. Heinz
Ernest F. Koschineg, III
Jessica M. Heinz
450 Sentry Parkway E, Suite 200
Blue Bell, PA 19422
Tel.: 610-567-0700
Fax: 610-567-0712
ekoschineg@c-wlaw.com
jheinz@c-wlaw.com

Attorneys for Aurobindo Pharma USA, Inc., Aurobindo Pharma LTD., and Aurolife Pharma, LLC

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on July 22, 2021, I electronically filed the foregoing document with the Clerk of the Court by using the CM/ECF system which will send a notice of electronic filing to all CM/ECF participants in this matter.

/s/ Jessica M. Heinz
Jessica M. Heinz